Drugs.com - Clinical Trials

Early Results from Johnson & Johnson’s Trispecific Antibody JNJ-5322 Show Promising Response in Heavily Pretreated Multiple Myeloma Patients

Chicago (June 3, 2025) – Johnson & Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma. Among the 36...

Jun 3, 2025 - 22:55
 0
Early Results from Johnson & Johnson’s Trispecific Antibody JNJ-5322 Show Promising Response in Heavily Pretreated Multiple Myeloma Patients
Chicago (June 3, 2025) – Johnson & Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma. Among the 36...
Read More

Tags:

Previous Article

Rilzabrutinib Granted Orphan Drug Designation in the US for Sickle Cell Disease

Next Article

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of...

Related Posts

FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

FDA Announces Plan to Phase Out Animal Testing Requirem...

May 12, 2025  0

PIVOT-PO Phase III Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

PIVOT-PO Phase III Study for Tebipenem HBr Stopped Earl...

Jun 3, 2025  0

NIH Study Reveals How Inflammation Makes Touch Painful

NIH Study Reveals How Inflammation Makes Touch Painful

May 12, 2025  0